[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591387":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":29,"centralContacts":33,"locations":42,"responsibleParty":59,"collaborators":24,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":68,"sex":69,"minAge":70,"maxAge":24,"enrollmentInfo":71,"targetDuration":24,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients","Minor patients (8 years of age or older) and adult patients seen consecutively in a hematology consultation as part of the follow-up of their thrombocytopenia.",[12,13],"Biological: blood sampling","Other: self-administrated questionaires",{"label":15,"type":6,"description":16,"interventionNames":17},"Control group","Control group (n=80) who will consist of healthy adult subjects (without pathology and without treatment) matched by age (± 5 years) and sex to adult patients included in the study given the possible influence of age and sex on circulating BDNF concentrations",[12,13],[19,25],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","blood sampling","3 blood tubes will be taken during a standard check-up",[15,9],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"self-administrated questionaires","4 self administrated questionaires and scales at the inclusion",[15,9],[30],{"name":31,"affiliation":5,"role":32},"Nadine Ajzenberg","PRINCIPAL_INVESTIGATOR",[34,38],{"name":31,"role":35,"phone":36,"phoneExt":24,"email":37},"CONTACT","01 40.25.62.73","nadine.ajzenberg@aphp.fr",{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},"Georges Jourdi","01.49.95.64.11","georges.jourdi@aphp.fr",[43],{"facility":44,"status":45,"city":46,"state":24,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Hôpital Bichat-Claude Bernard","RECRUITING","Paris","75018","France","FR",{"type":51,"coordinates":52},"Point",[53,54],2.3488,48.85341,{"lat":54,"lon":53},[57,58],{"name":31,"role":35,"phone":36,"phoneExt":24,"email":37},{"name":39,"role":35,"phone":40,"phoneExt":24,"email":41},{"type":60,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100591387","research-for-plasma-biomarkers-associated-with-fatigue-in-thrombocytopenic-patients-100591387",false,"NCT06979765","Research for Plasma Biomarkers Associated With Fatigue in Thrombocytopenic Patients","FAGPLAQ","Inclusion criteria for patients (adults or minors):\n\n* Patients with constitutional or autoimmune (chronic or persistent ITP with last treatment administration ≥ 3 weeks) thrombocytopenia (platelet count \\\u003C 150×109\u002FL) already diagnosed\n* patient not being treated and not receiving serotonin reuptake inhibitor (SSRI) or norepinephrine (SNRI) or antithrombotic treatments (antiplatelet or anticoagulant) in the 10 days prior to inclusion\n* affiliation to social security (beneficiary or assignee)\n* patient followed in consultation in one of the recruiting haematology departments\n* Patient (or parent) having received a detailed explanation of the research project and having consent by signing the consent form before any research-specific procedure\n\nInclusion criteria for healthy volunteers:\n\n* Age- (± 5 years) and sex-matched healthy adult controls\n* Non-thrombocytopenic patients and not receiving antithrombotic, SNRI or SSRI therapy or if applicable, last treatment ≥ 10 days\n* affiliation to social security (beneficiary or assignee)\n* adults who received a detailed explanation of the research project and having consent by signing the consent form before any research-specific procedure\n\nNon inclusion criteria (adults and minors):\n\n* Adult patients under legal protection (guardianship or curatorship) Thrombocytopenic patients treated with antithrombotics, serotonin reuptake inhibitors (SSRIs) or noradrenaline reuptake inhibitors (SNRIs)\n* Minor patients weighing less than 20 kg\n\nNon inclusion criteria for healthy adult controls:\n\n* Healthy adult volunteers under legal protection (guardianship, curatorship or safeguard of justice).\n* Pregnant women",true,"ALL","8 Years",{"count":72,"type":73},280,"ESTIMATED","INTERVENTIONAL",[76],"NA","Thrombocytopenia is a clinical problem defined by a platelet count lower than 150×10⁹\u002FL. It can be linked to various pathologies of central origin, such as decreased platelet production in the bone marrow, or peripheral origin with increased platelet destruction through autoimmune mechanisms, increased splenic sequestration, or excessive platelet consumption. Significant fatigue is often reported in association with thrombocytopenia, but its underlying pathophysiology remains unclear. One hypothesis is the role played by neurotrophic factors contained in platelets and released into the circulation following their activation, in particular the Brain-Derived Neurotrophic Factor (BDNF), which promotes the survival, growth, differentiation, and plasticity of neurons in both the central and peripheral nervous systems. Consequently, BDNF plays a key role in long-term memory, intellectual abilities, and neuroprotection.\n\nIn this context, this project aims to confirm whether platelet-origin neurotrophic biomarkers could explain the fatigue experienced by thrombocytopenic patients and whether it depends on the etiology of the thrombocytopenia.",[79],"Thrombopenia",[79],"2026-02-02",{"date":83,"type":84},"2026-02-03","ACTUAL",{"date":86,"type":84},"2025-03-26",{"date":88,"type":73},"2028-06-26",{"name":5,"class":6},1]